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Background: A majority of patients with cystic fibrosis (CF) become colonised with Aspergillus fumigatus (Af.), but only a minority
develops allergic bronchopulmonary aspergillosis (ABPA). ABPA is associated with increased levels of specific immunoglobulin G (IgG)
anti-Af. antibodies with a characteristic IgG subclass distribution. We examined whether this characteristic immune response was under the
influence of GM and KM allotypes, which are genetic markers (antigenic determinants) on gamma- and kappa-light chains, respectively.
Methods: Sera from 233 CF patients were typed for seven GM determinants and two KM determinants. The types were correlated to IgG
subclass anti-Af. antibody levels and to the presence or absence of Af. colonisation as well as ABPA. Results: The IgG2 antibody level was
significantly higher in heterozygous GM (1,2,17 23 5,21 and 1,3,17 23 5,21) compared to homozygous GM allotypes ( p = 0.02). Patients
with the same allotypes tended to have higher IgG1 ( p = 0.051). In patients with ABPA, being heterozygous for G1M and G3M was linked to
higher IgG4 and lower IgG3 as compared to the other genotypes. The KM markers did not influence the antibody levels. The allotype GM(3
23 5), associated with atopic bronchial asthma, tended to make a relatively larger group in ABPA patients compared to non-ABPA and
patients not colonised with Af. ( p = 0.09). Conclusions: An influence of the GM allotypes on the immune response to Af. and on the
development of ABPA in patients with CF is suggested.
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Patients with cystic fibrosis (CF) are frequently colonised
in the airways with Aspergillus fumigatus (Af.) with a
cumulative incidence around 57% [1] but with a wide range
from under 5% to almost 100% in different reports [2–4].
Differences in the frequency of sampling and in culture
techniques are variables that may explain this wide range. A
minority of patients, ranging from 1% to 14% in various
studies [4–7], develops a complicating hypersensitivity
reaction termed allergic bronchopulmonary aspergillosis
(ABPA), which is characterised by a dual type immuno-1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.048
Abbreviations: Af., Aspergillus fumigatus; ABPA, allergic bronchopul-
monary aspergillosis; Asp., Aspergillus; CF, cystic fibrosis; PA, Pseudo-
monas aeruginosa.
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E-mail address: mskov@dadlnet.dk (M. Skov).globulin G (IgG) and IgE humoral antibody response
[1,8,9]. The diagnosis is sometimes difficult and rests upon
a set of generally accepted criteria [4,10,11].
The four human immunoglobulin G (IgG) subclasses
(IgG1–4) differ in their biological properties and have,
except for IgG4, their own constellation of hereditary
antigenic determinants, called GM allotypes, located on
the C region of 1,2 and 3 [12]. KM allotypes are hereditary
antigenic determinants of the K-type light chains. Various
studies have demonstrated that the specific antibody re-
sponse to different infectious agents is in part subclass-
specific. IgG1 and IgG3 primarily represent responses to
viral proteins [13], IgG2 dominate in response to bacterial
polysaccharides [14] and IgG4 to human filariasis [15]. In
patients with CF and complicating ABPA, the specific IgG
anti-Af. antibodies are predominantly found in the IgG1,
IgG2 and IgG4 subclasses [16]. In chronic Pseudomonas
aeruginosa (PA) infection in patients with CF, a specificed by Elsevier B.V. All rights reserved.
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correlated to poor lung function and poor clinical condition
[17]. Furthermore, IgG3 antibody levels are significantly
increased in sera homozygous for GM (3 5), lower in
heterozygous sera and significantly lower in sera homozy-
gous for GM (1,2,17 21) [18]. As certain GM and KM
allotypes associate with the immune responsiveness to
particular infectious pathogens [19], we wanted to examine
whether there is a similar link between certain GM allo-
types, the levels of IgG subclasses and the presence of
ABPA in patients with CF.2. Patients and methods
2.1. CF patients
The diagnosis of CF was established on the basis of
abnormal sweat electrolytes, characteristic clinical features
and CF genotype. All patients are seen on a regular monthly
basis in the outpatient clinic. Lower respiratory tract secre-
tions are obtained at each visit by expectoration or nasolar-
yngeal suction and microbiological studies include plating
on Sabaroud maltose agar (pH = 4) to detect fungal growth.
Biochemical markers of ABPA including specific anti-Af.
IgG and IgE antibodies, eosinophil leukocyte counts, and
total serum IgE are determined at least once every year.
Because the diagnostic parameters of ABPA often fluctuate
over time in individual patients according to disease activity,
we purposely pooled data from a prolonged observational
period of 5 years to allocate patients into three groups. GM
allotypes do not change over time, and misclassification of
ABPA was minimised.
(a) ABPA-group: Patients with positive culture for Af.
(positive Aspergillus cultures for at least 6 months per
year) as well as increased levels of both precipitating
antibodies to Af. and specific anti-Af. IgE antibodies
were included [median age 16.5 years (9–37), n = 26].
These patients fulfilled the commonly accepted criteria
for ABPA [1,3,4] [mean 6.4 positive criteria (range 6–8)
at least once within the observation period]. The most
recent accepted criteria for ABPA include five positive
criteria to confirm the diagnosis [11].
(b) Non-ABPA group: Patients with positive sputum
cultures (positive Aspergillus cultures for at least 6
months per year) but without increased levels of the
diagnostic markers were included (median age 19 years
(9–44), n = 35). Patients in groups a and b had a similar
distribution of chronically and intermittently PA
infected patients as well as distribution of males/
females.
(c) Non-Aspergillus (Asp.) group: Patients with no or only
rare [ < 10% (median) of total] positive cultures and
without specific antibodies were included [median age
18 years (1–45), n= 172]. Some patients in this groupwere born within the study period and therefore had an
observation period below 5 years.
There was no age difference within the three groups
(Kruskal–Wallis test, p < 0.05). The study population rep-
resents 88% of the total population of patients with CF in
the centre (in 30 patients, measurements of either IgG
subclasses or GM allotypes had not been performed).
2.2. Follow-up
Within the period 1995–2001, additional 18 patients
were diagnosed with ABPA. In three of these patients,
GM haplotypes have not been determined.
2.3. Determination of total IgG and IgG subclass antibodies
to A. fumigatus in sera
Total IgG and the subclasses IgG1, IgG2, IgG3 and IgG4
to Af. were measured by ELISA as previously described and
published [16,17]. The serum samples were taken ‘‘at
random’’ within 6 months independently of disease activity.
Following the disintegration of mycelial mats of Af. strain
ATCC 42202 in an X-press operated at a maximal force of
200 MPa at  30 jC, preparation of water-soluble somatic
hyphal (WSSH) antigens was prepared as described else-
where [20]. The values were determined in relation to a
logarithmic curve drawn from results of a standard serum
pool and expressed in ELISA units (EU) [16].
2.4. Determination of allotypes
The GM allotypes are expressed as amino acid sequences
on the constant region of the heavy chains (chromosome 14,
band q 32) and KM allotypes on the kappa light chains
(chromosome 2, band p 12). They are inherited in a
codominant Mendelian way, in fixed combinations called
haplotypes. GM allotypes are restricted to one subclass and
located on the heavy chains of IgG1, IgG2 or IgG3.
Immunoglobulin allotypes were determined by haemagglu-
tination inhibition using specific antibodies against GM and
KM markers (epitopes) [21]. In Caucasians, the G1M(1) and
G1M(3) are alternative alleles for IgG1, G3M(5) and
G3M(21) are alternative alleles for IgG3, whereas there is
only one marker G2M(23) for IgG2. For the kappa light
chains, KM(3) and KM(1) are alternative alleles. The serum
samples were types for G1M(1) and G1M(3), G2M(23),
G3M(5) and G3M(21), as well as for KM(1) and KM(3).
They were also tested for two additional IgG1 markers:
G1M(2) and G1M(17), which are variably expressed on
IgG1 molecules and therefore do not mutually exclude each
other or G1M(1) and G1M(3). For some of the present
analysis, the patients were divided into groups according to
the most frequent phenotypes based upon the mutually
exclusive markers on IgG1 and IgG3—the presence or
absence of the IgG2 marker—and the two KM markers.
Table 2
GM and KM types according to IgG and IgG subclass antibodies to
Aspergillus fumigatus in 233 patients with cystic fibrosis
Number IgG IgG1 IgG2 IgG3 IgG4
Homozygote for G1M(3) and G3M(5)
3 5
3 23 5 94 19.5 8 20 12.8 15
Homozygote for G1M(1) and G3M(21)
1,2,17 21
1,17 21 30 18 9.1 19.5 13.3 15
ystic Fibrosis 3 (2004) 173–178 1752.5. Statistical analysis
The Mann–Whitney test was used for nonparametric
unpaired data where two groups were compared. Single- or
two-factor analysis of variance (ANOVA) and Kruskal–
Wallis test for nonparametric data were used when more
than two groups were compared. Calculations were per-
formed using StatView 4.5 as software. For the ANOVA
tests, data were log transformed before calculations. Their
level of significance was 5% for two-tailed comparison.




1,3,17 23 5,21 102 28 12.6 25.5 12.4 16
GM 23
positive 127 23 10 22 12.8 15
negative 99 20 10.4 22 12 16
KM
1,3 31 18 10 24 13.2 15
3 195 24 10 22 12.8 16
Values are medians of the groups given as ELISA units (EU).3. Results
3.1. GM phenotype distribution
The frequencies of GM phenotypes in the 233 CF
patients were comparable to the distribution observed in
groups of healthy Caucasian controls (n = 86) [22] and
(n = 430) [23].
3.2. GM allotypes and IgG subclass antibodies to A.
fumigatus
The entire patient population represented 15 different
phenotypes. Table 1 gives the median levels of specific anti-
Af. antibodies for each of the four IgG subclasses as well as
for total IgG for each GM phenotype. Five of the pheno-
types including only one or two patients were excluded from
the statistical calculations (n = 7). No significant difference
in IgG subclass (1–4) antibody levels according to the
remaining eight GM phenotypes was found (Table 1).
Following exclusion of the five rare phenotypes, the rest
of the patients (n = 226) could be allocated to one of three
groups according to the IgG1 and IgG3 markers: homozy-Table 1
The distribution of GM phenotypes and IgG subclass antibodies to
Aspergillus fumigatus in 233 patients with cystic fibrosis
GM phenotype Number
of patients
IgG IgG1 IgG2 IgG3 IgG4
1,17 21 10 14.5 9.3 19.5 13.4 14.5
1,17 23 21 2 46 109 110 16.5 15.3
1,17 23 5,21 1a 14 4.8 22 9 15
1,2,17 21 17 18 9 17 12 16
1,2,17 23 21 1 14 8.4 17 14.4 16
1,2,17 23 5,21 2a 21 23.7 34.5 10.3 10
1,2,3,17 5,21 15 30 30 30 11.6 16
1,2,3,17 23 5 1a 36 5.6 54 26 14
1,2,3,17 23 5,21 19 31 11 64 14.4 26
1,3,17 23 21 1a 36 124 42 15 128
1,3,17 21 2a 14.2 101 125 18.5 36
1,3,17 5,21 34 25.5 11.5 28 11.5 16
1,3,17 23 5,21 34 30 11.9 22 12.4 15
3 5 23 20 10 19 13.2 16
3 23 5 71 19 7.6 20 12.8 15
The antibody level is given as ELISA units (EU).
a Indicates patients left out of the calculations.gous for G1M(3) and G3M(5) [n = 94], homozygous for
G1M (1) and G3M(21) [n = 30] and heterozygous for
G1M(1/3) and G3M(5/21) [n = 102; Table 2]. The 226
patients were also divided in two groups according to the
presence or absence of the IgG2 marker G2M(23) [Table 2]
and in two groups according to the KM markers (Table 2).
The IgG2 antibody level was highest in the patients hetero-
zygous for the IgG1 and IgG3 markers ( p = 0.02) as
compared to the patients homozygous for these markers
(Table 2). The heterozygous patients also tended to have
higher IgG1 ( p = 0.051) and IgG4 ( p = 0.11) than the two
homozygous groups (Table 2), whereas no difference was
observed between homozygous and heterozygous for IgG3
and IgG4. The presence or absence of the IgG2 marker
G2M(23) could not be linked to the total or IgG subclass
antibody levels (Table 2), nor could the two KM markers.
Homozygous KM(1/1) is very rare and was not found in our
patients.
3.3. GM allotypes and A. fumigatus status
The levels of total IgG and IgG subclass antibodies
against Af. according to GM and KM allotypes in the three
patient groups, ABPA, non-ABPA and non-Asp., are shown
in Table 3. All levels were in general increased in non-
ABPA as compared to non-Asp., and even more in the
ABPA group. The association of increased IgG2 levels and
being heterozygous for the GM markers on IgG1 and IgG3
found in the entire population (Table 2) did not reach
statistical significance when the patients were split into the
three groups which could be due to smaller patient sample
groups.
Table 3
GM genotypes in 226 patients with cystic fibrosis distributed in groups of ABPA, non-ABPA and non-Aspergillus patients
Genotypes ABPA (n= 24) non-ABPA (n= 31) non-Aspergillus (n= 171)
IgG IgG IgG
number 1 2 3 4 number 1 2 3 4 number 1 2 3 4
3 5 13 72 120 17 52 8 10.2 50 20.5 17 73 7 17 11 15
1,2,3,17 5,21 3 210 110 17 84 9 43 58 19 66 22 9.5 25 11.1 16
1,3,17 5,21 7 110 180 15 88 8 22.5 24.5 11.3 15.5 53 10 22 12 15
1,17 21 1 560 340 34 74 1 180 140 20 18 10 9.3 19.5 12.9 13.5
1,2,17 21 0 5 100 28 12 25 13 8.2 16 13.6 10
GM 23
positive 16 78 115 16.5 56 16 17 29.5 17 18.5 95 8 19 12 14
negative 8 172 260 14.5 82 15 48 68 15 19 76 8.6 18.5 11.3 15
KM
1,3 4 215 598 23 90 7 24 132 12 66 20 7.3 20 11.3 13
3 20 87 143 16 75 24 19.5 38 17 18.5 151 8.4 19 12 15
Seven patients who did not belong to any of the three groups were left out of calculations. Values are medians given as ELISA units (EU).
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and the non-ABPA group, Table 3 shows that levels of
IgG1, IgG2 and IgG4—but not IgG3—increased in the
ABPA group. The increase was seen in all GM and KM
groups, but when the levels in the two KM groups in the
ABPA patients were compared, it appears that levels of all
four IgG subclasses were higher in the heterozygous KM(1/
3) than in the homozygous KM(3/3) patients (Table 3).
Similarly, in the ABPA patients, the levels of IgG1, IgG2
and IgG4 were higher in the G2M(23)-negative patients
than in the G2M(23)-positive patients (Table 3). Finally, the
number of patients in the three groups was not randomly
distributed. Table 3 shows that 54% of the ABPA patients
were homozygous for G1M(3) and G3M(5) versus only
26% in the non-ABPA patients ( p = 0.09). Also, 67% of the
ABPA patients were positive for G2M(23) versus 52% of
the non-ABPA patients.
Patients who developed ABPA within the period 1995–
2001 had a similar distribution of GM haplotypes, except
that a few more were heterozygous for G1M and G3M.
Eight of fifteen patients were heterozygous for G1M and
G3M, six patients were homozygous for GM (3 5) and only
one patient was homozygous for GM(1,17 21). GM(23)
positivity was found in 8 of 15 patients, 2 patients were
KM(1,3) and 13 patients were KM(3).4. Discussion
4.1. Association between GM and KM allotypes and specific
anti-Af. antibody levels
We found the frequency of GM allotypes to be the same
as in the normal Caucasian background population [22].
Indeed, it would not be expected that CFTR mutations
should be linked to genes coding for immunoglobulin. It
appears that polymorphisms at the level of immunoglobulingenes are not related to survival in patients with CF because
this would have created a selection bias and a distribution of
GM allotypes differing from the normal population.
The results of determination of IgG and IgG subclass
antibodies against Af. in the total patient population did not
differ among the 15 GM allotypes detected. Seven of the
phenotypes were however represented by only one or two
patients (Table 1). After exclusion of these patients, the
remaining 226 could be pooled to form three groups: two
homozygous for IgG1 and IgG3 markers (3 5 and 1 21) and
one heterozygous (Table 2). We now found that the hetero-
zygous patients had the highest levels of specific anti-Af.
antibodies in subclasses IgG1, IgG2 and IgG4, although
only reaching significance for IgG2 (Table 2). Looking only
at the ABPA patients versus the non-ABPA patients, the
latter being equally exposed to Af. as the ABPA patients, the
heterozygous patients had higher levels of specific IgG4
antibodies than the two homozygous groups (Table 3). The
levels of IgG1 and IgG2—but not IgG3—antibodies were
also higher in the heterozygous group compared to the
G1M(3) and G3M(5) homozygous groups. Only one ABPA
patient was homozygous for G1M(1) and G3M(21), and
levels cannot be properly evaluated. IgG subclass antibody
levels were significantly higher in ABPA patients as com-
pared to non-ABPA patients although the ABPA population
was a pool of all ABPA patients irrespective of ABPA
activity. We purposely chose not to split up in subgroups
due to the limited number of patients and because GM
haplotypes do not change over time. Furthermore, the
treatment of ABPA within the study period tended to be a
longterm treatment, i.e., years, which may confound the
actual disease activity.
An association between heterozygosity for IgG1 and
IgG3 markers and significantly increased total IgG4 anti-
bodies has been reported in normal healthy individuals [24].
Increased levels of IgG4 have been found in filarial infec-
tions [15,25]. Eosinophilia is characteristic of filarial infec-
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and all three conditions are associated with increased IgG4
levels [15,16,26]. We have previously shown that IgG4
antibodies against Af. have the highest diagnostic specificity
of the four subclasses in ABPA [16]. There are no allotypic
markers for IgG4, but it has been suggested that the GM(3
23 5) exerts a positive effect on IgG4 levels in normal sera
[27]. The present study failed to confirm this effect. Some
studies have reported an association between patients being
homozygous for GM(3 5) and having high levels of IgG3
[18,28–31], which could not be confirmed by Morell et al.
[24] in healthy control donors nor in the present study.
The presence of the IgG2 G2M(23) marker has been
associated to high total IgG2 antibodies [24,28,29] but was
not found in the present study, as well as we, in concordance
with most other studies [24,28–30], neither found an
association between the presence of G2M(23) and increased
IgG4.
The linkage between KM allotypes and IgG subclasses
appear to vary. Patients with CF and complicating chronic
Pseudomonas aeruginosa infection who were homozygous
for KM(3) had increased anti-PA IgG2 antibodies [18] as
well as increased IgG1 [31]. Using Af.-specific antigens in
the selected group of ABPA patients KM markers did not
influence the antibody levels (Table 3). KM allotypes are
located on the light chains and are not restricted to one class
or subclass of immunoglobulins [21], which may in part
result in different associations.
4.2. Association between GM and KM allotypes and the
presence of ABPA
It appears from the data shown in Table 3 that the
different haplotypes were not always randomly distributed
among the three groups of patients: ABPA, non-ABPA and
non-Asp. However, the rather small sample sizes have to be
taken into account. Fifty-four percent of the ABPA patients
were homozygous for G1M(3) and G3M(5) versus 26% of
the non-ABPA patients. If the ABPA patients in the follow-
up group (n = 15) were included, the percentage of patients
homozygous for G1M(3) and G3M(5) was 49%. The
follow-up group has a relatively larger group of patients
being heterozygous, i.e., in total 46% of the ABPA patients.
An association between the phenotype GM(3 23 5) and
atopic asthma has been reported by Oxelius et al. [26], and it
is therefore noteworthy that in the relatively large group of
GM(3 5) in the ABPA patients, the majority (11/13) was
GM(3 23 5) and only two were GM(3 5). Children with
atopic bronchial asthma have been shown to have an
imbalanced class switch in the rearrangement of the genes
for IgG [32].
It has been suggested that GM and KM allotypes
themselves may not influence disease susceptibility, but
the associations may reflect linkage disequilibrium with
other polymorphisms of the constant region genes or with
specific variable region genes [33]. Isotype switching hasbeen suggested for the mechanisms involved in GM allotype
effect on the IgG subclass concentrations [34]. The amino
acid and codon substitutions correlating with allotypes are
cloned in several instances. Allotyping at the genomic level
by PCR may increase the capacity to precisely relate
polymorphic variants to particular functions and pathophys-
iological events [35,36].
We have shown that ABPA associates to a specific IgG
subclass pattern and to a specific TH-2 cytokine profile with
significantly increased IL-4 and IL-5 in ABPA patients as
compared to non-ABPA patients [37]. IL-4 is a critical
mediator of B-cell switching to IgE as well as IgG4
synthesis. Markers around the IL-4 locus on chromosome
5q31.1 linked to a gene controlling IgE levels, GM allotypes
on chromosome 14q32 and six HLA-DR2/5 subtypes on
chromosome 6 reported to be of pathophysiological impor-
tance to ABPA [38] indicate a polygenic inheritance of the
immune response.
The linkage between being heterozygous for G1M and
G3M, having increased IgG1, IgG2 and IgG4 subclasses as
well as G2M(23) and having ABPA, suggests a GM
allotypic influence on the immune response. GM allotyping
may contribute to the identification of CF patients at risk of
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